"The next PR we get is very likely news of the outcome of the B-OM end-of Phase 2 FDA meeting. That is, if it's good news: ie, can proceed to Phase 3. Great news would be BTD. Company said they are arranging it for end of September, but that is an expectation, not a definite. "
That's not what the Company said at all.
Per the 10-K:
"In September 2018, the Company plans to submit a request to FDA for an End-of-Phase 2 meeting."